Treatment Strategies in Alzheimer’s Disease with a Focus on Early Pharmacological Interventions

Gauthier S, Grundmann M. Alzheimer’s disease: trial designs to establish disease modification. In: Gauthier S, Cummungs JL, editors. Alzheimer’s disease and related disorders annual 2002. London: Martin Dunitz, 2002: 77–85 Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985–92 Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. The Tacrine Collaborative Study Group. N Engl J Med 1992; 327: 1253–9 Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–8 Gurka P, Bacher R, Kemmler G, et al. Pharmacological treatment strategies of residential primary care providers in dementia diseases: results of a representative survey in western Austria. Pharmacopsychiatry 2002; 35: 144–9 Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122–6 DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51: 145–55 Kobayashi K, Miyazu K, Fukutani Y, et al. Morphometric study on the CH4 of the nucleus basalis of Meynert in Alzheimer’s disease. Mol Chem Neuropathol 1991; 15: 193–206 Rogers SL. Perspectives in the management of Alzheimer’s disease: clinical profile of donepezil. Dement Geriatr Cogn Disord 1998; 9Suppl. 3: 29–42 Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–8 Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445–9 Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002; 109: 1053–65 Santos MD, Alkondon M, Pereira EF, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 2002; 61: 1222–34 Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11: 131–45 Winblad B. Maintaining functional and behavioral abilities in Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15Suppl. 1: S34–40 Arias C, Becerra-Garcia F, Tapia R. Glutamic acid and Alzheimer’s disease. Neurobiology 1998; 6: 33–43 Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegener-ation in Alzheimer disease: new hypothesis and new therapeutic strategies. Arch Neurol 1997; 54: 1234–40 Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91–104 Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–46 Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41 Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003; 18: 81–5 Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21; 291(3): 317–24. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–8 Yesavage JA, O’Hara R, Kraemer H, et al. Modeling the prevalence and incidence of Alzheimer’s disease and mild cognitive impairment. J Psychiatr Res 2002; 36: 281–6 DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2: 15–21 Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2003; 2: 646–53 Jelic V, Winblad B. Treatment of mild cognitive impairment: rationale, present and future strategies. Acta Neurol Scand Suppl 2003; 179: 83–93 Giacobini E. Cholinesterase inhibitors stabilize Alzheimer’s disease. Ann N Y Acad Sci 2000; 920: 321–7 Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25–35) in rat PC12 cells. Neuroreport 1998; 9: 1519–22 Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 2000; 54: 588–93 Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295–301 Thal LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 2000; 55: 805–10 Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both, as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336: 1216–22 Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002; 8: 126–32 Phiel CJ, Wilson CA, Lee VM, et al. GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 2003; 423: 435–9 Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–7 Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A 2003; 100: 2023–8 Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 2003; 38: 547–54 Ada G. Vaccines and vaccination. N Engl J Med 2001; 345: 1042–53 Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer’s disease. Drugs Aging 2003; 20: 101–13 Skoog I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother 1997; 51: 367–75 Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046–52 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64 Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–75 Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517–21 Rogers J, Webster S, Lue LF, et al. Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging 1996; 17: 681–6 int’Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001; 345: 1515–21 Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414: 212–6 Zhou Y, Su Y, Li B, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho. Science 2003; 302: 1215–7 Tabet N, Feldmand H. Ibuprofen for Alzheimer’s disease. Cochrane Database Syst Rev 2003; (2): CD004031 Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627–31 Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439–43 Kirsch C, Eckert GP, Koudinov AR, et al. Brain cholesterol, statins and Alzheimer’s disease. Pharmacopsychiatry 2003; 36: 113–9 Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 2002; 15: 445–50 Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 2001; 16: 1043–53 Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996; 46: 130–5 Holmes C, Arranz MJ, Powell JF, et al. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer’s disease. Hum Mol Genet 1998; 7: 1507–9 Tariot PN. Medical management of advanced dementia. J Am Geriatr Soc 2003; 51: S305–13 Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 2002; 14: 389–404 Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer’s disease. Int Psychogeriatr 2002; 14Suppl. 1: 93–126 Cummings JL. Cholinesterase inhibitors: a new class of psycho-tropic compounds. Am J Psychiatry 2000; 157: 4–15 Robert P. Understanding and managing behavioural symptoms in Alzheimer’s disease and related dementias: focus on rivastigmine. Curr Med Res Opin 2002; 18: 156–71 Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–76 Kindermann SS, Dolder CR, Bailey A, et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging 2002; 19: 257–76 Lyketsos CG, Del Campo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60: 737–46 Mortimer JA, Ebbitt B, Jun SP, et al. Predictors of cognitive and functional progression in patients with probable Alzheimer’s disease. Neurology 1992; 42: 1689–96 Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14 Price DL, Tanzi RE, Borchelt DR, et al. Alzheimer’s disease: genetic studies and transgenic models. Annu Rev Genet 1998; 32: 461–93 Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intra-cellular Aß and synaptic dysfunction. Neuron 2003; 39: 409–21 Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999; 2: 271–6 Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J Neurosci 2003; 23: 7504–9 Ballard C, O’Brien J, Morris CM, et al. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16: 499–503 Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer’s disease: prospective analyses from the Predictors Study. Neurology 1994; 44: 2300–7 Mohs RC, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer’s disease. Stat Med 2000; 19: 1401–9 Houlden H, Crook R, Backhovens H, et al. ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer’s disease families. Am J Med Genet 1998; 81: 117–21 Farlow MR, Lahiri DK, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology 1998; 50: 669–77 Salmon DP, Thomas RG, Pay MM, et al. Alzheimer’s disease can be accurately diagnosed in very mildly impaired individuals. Neurology 2002; 59: 1022–8 Scheltens P, Fox N, Barkhof F, et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002; 1: 13–21 Kantarci K, Xu Y, Shiung MM, et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer’s disease. Dement Geriatr Cogn Disord 2002; 14: 198–207 Herhol K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002; 17: 302–16 Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003; 2: 605–13 Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer’s disease. Proceedings of the biological markers working group: NIA initiative on neuroimaging in Alzheimer’s disease. Neurobiol Aging 2003; 24: 521–36 Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis Assoc Disord 1999; 13Suppl. 2: S9–19 Lamb HM, Goa KL. Rivastigmine: a pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics 2001; 19: 303–18 Caro JJ, Salas M, Ward A, et al. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in The Netherlands. Dement Geriatr Cogn Disord 2002; 14: 84–9 Jonsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther 1999; 21: 1230–40 Rice DP, Fillit HM, Max W, et al. Prevalence, costs, and treatment of Alzheimer’s disease and related dementia: a managed care perspective. Am J Manag Care 2001; 7: 809–18 Wimo A, Winblad B, Stoffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 2003; 21: 327–40 Ritchie K, Robine JM, Letenneur L, et al. Dementia-free life expectancy in France. Am J Public Health 1994; 84: 232–6 Michaelis ML. Drugs targeting Alzheimer’s disease: some things old and some things new. J Pharmacol Exp Ther 2003; 304: 897–904